Trials / Completed
CompletedNCT00794443
ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients
A Multi-center Double-blind Parallel-group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation.
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 692 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center double-blind parallel-group study in involutional osteoporosis patients to compare the efficacy and safety of monthly oral intermittent formulation ONO-5920/YM529 with its daily formulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM529 / ONO-5920 | Oral |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2008-11-20
- Last updated
- 2015-05-04
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00794443. Inclusion in this directory is not an endorsement.